{'fraction_non_alphanumeric': 0.0176678445229682, 'fraction_numerical': 0.02120141342756184, 'mean_word_length': 5.670588235294118, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Highlights from the literature

EUROPEAN GUIDELINES ON ATRIAL FIBRILLATION Recently published guidelines by the European Society of Cardiology on the management of atrial fibrillation are the focus of attention in the BMJ (2011;342:989e90). In keeping with previous guidance, the top priority for management remains the prevention of stroke. The direct thrombin inhibitory agent dabigatran is of considerable potential interest in this respect as, unlike warfarin, it does not require therapeutic monitoring and it appears to have lower associated risks of bleeding.